RCT – 2ry analysis | Omega-3 supplementation linked to increased AF risk in post-MI patients

Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial – Clinical Nutrition

Related:

M-A: Omega-3 fatty acids supplementation is associated with increased risk of atrial fibrillation.

M-A: Omega-3 fatty acids supplementation increases the risk of atrial fibrillation in patients with lipid disorders.

More data suggests no cardiovascular benefit from Omega-3 supplementation – secondary analysis of STRENGHT trial did not show an association between achieved Omega-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk.

RCT: Omega-3 supplements do not reduce cardiovascular events in elderly patients after myocardial infarction

#AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk

Meta-Analysis of Randomized Trials: Little Benefit from Omega-3 Intake to Reduce Cardiovascular Disease Risk

Commentary from the author on Twitter (thread – click for more)

RCT data consistently show that Omega-3 suppl increase AF risk https://t.co/LQVHfPNtKL

In this substudy of the #OMEMI trial we add novel data from thumb-ECG screening and serum EPA/DHA, supporting a causal relation between omega-3 (EPA) and AF!https://t.co/B9VoDNQpZi

? 1/4 pic.twitter.com/GFYGfVaNMq

— Peder L. Myhre ? (@pmyhre) July 28, 2023